Depomed Inc (NASDAQ: DEPO) announced Thursday that it will acquire the U.S. rights to the NUCYNTA franchise from Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals, Inc. for $1.05 billion. According to the company’s press release, “The NUCYNTA franchise. Read More. Don t Miss Any Updates! News Directly in Your Inbox Subscribe to: